VX-322: A Novel Dual Receptor Tyrosine Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia

In acute myelogenous leukemia (AML), the FLT3 receptor tyrosine kinase (RTK) is highly expressed with 30% of patients expressing a mutated, constitutively active form of this protein. To inhibit this receptor, VX-322 was developed and found to be very potent against both the FLT3 and c-KIT RTKs with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2012-01, Vol.55 (2), p.725-734
Hauptverfasser: Heidary, David K, Huang, George, Boucher, Diane, Ma, Jianguo, Forster, Cornelia, Grey, Ron, Xu, Jinwang, Arnost, Michael, Choquette, Deborah, Chen, Guanjing, Zhou, Jie-Hua, Yao, Yung-Mae, Ball, Edward D, Namchuk, Mark, Davies, Robert J, Henkel, Greg
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!